Companies Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals (TARS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Tarsus Pharmaceuticals, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers27th pct.Of 15 peer CEOs
CEO pay, last three years
- $3,130,332FY2023
- $7,896,192FY2024
- $6,617,979FY2025
CEO total pay was $6,617,979 in fiscal 2025, down from $7,896,192 in fiscal 2024.
FY2025: salary $726,333 · bonus $0 · stock awards $2,648,284 · option awards $2,651,487
Executives and directors
Aziz Mottiwala · CCOBobak Azamian · CEOBryan Wahl · General CounselJeffrey Farrow · CFOSeshadri Neervannan · COOAndrew Goldberg · Independent DirectorBhaskar Chaudhuri · Independent DirectorDavid E.I. Pyott · Independent DirectorKatherine Goodrich · Independent DirectorRosemary Crane · Former director (through FY2025)Scott Morrison · Independent DirectorWendy Yarno · Lead Independent DirectorWilliam J. Link · Independent Director
Frequently asked questions
Who was the highest-paid executive at Tarsus Pharmaceuticals, Inc. in fiscal 2025?
As disclosed, Bobak Azamian (President, Chief Executive Officer and Board Chairman) was the highest-paid executive at Tarsus Pharmaceuticals, Inc. in fiscal 2025, with total compensation of $6,617,979.
How does Tarsus Pharmaceuticals, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Bobak Azamian's total compensation ranked at the 27th percentile of Tarsus Pharmaceuticals, Inc.'s disclosed peer group.
What is Tarsus Pharmaceuticals, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Tarsus Pharmaceuticals, Inc.'s CEO-to-median employee pay ratio was 26:1.
How did shareholders vote on Tarsus Pharmaceuticals, Inc.'s executive compensation?
As disclosed, 99.31% of shareholders supported Tarsus Pharmaceuticals, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Tarsus Pharmaceuticals, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Tarsus Pharmaceuticals, Inc. reported total board compensation of $1,233,948 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Bobak Azamian | $726,333 | $0 | $2,648,284 | $2,651,487 | $555,700 | $0 | $36,175 | $6,617,979 |
| President, Chief Executive Officer and Board Chairman | ||||||||
| Aziz Mottiwala | 529,250 | — | 983,361 | 984,518 | 260,100 | 0 | 32,300 | 2,789,529 |
| Chief Commercial Officer | ||||||||
| Jeffrey Farrow | 541,667 | 0 | 893,961 | 895,011 | 264,900 | 0 | 82,078 | 2,677,617 |
| Chief Financial Officer and Chief Strategy Officer | ||||||||
| Seshadri Neervannan | 547,000 | 0 | 893,961 | 895,011 | 267,300 | 0 | 24,900 | 2,628,172 |
| Chief Operating Officer | ||||||||
| Bryan Wahl | 500,833 | 0 | 893,961 | 895,011 | 245,500 | 0 | 24,900 | 2,560,205 |
| General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Bobak Azamian | $6,617,979 | $7,896,192 | $3,130,332 | ↓ −1,278,213 |
| Aziz Mottiwala | 2,789,529 | 3,138,862 | — | ↓ −349,333 |
| Jeffrey Farrow | 2,677,617 | 3,232,926 | 3,991,830 | ↓ −555,309 |
| Seshadri Neervannan | 2,628,172 | 3,194,689 | 1,741,918 | ↓ −566,517 |
| Bryan Wahl | 2,560,205 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program emphasizes long-term value creation that correlates with the growth of sustainable long-term value for our stockholders, as well as motivates, retains, and rewards our NEOs.
| CEO STI target (% of salary) | 70% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Bobak Azamian | RSU | 2025-03-05 | — | — | 59,512 | — | $2,648,284 |
| Seshadri Neervannan | OPTION | 2025-03-05 | — | — | 30,628 | — | 895,011 |
| Aziz Mottiwala | RSU | 2025-03-05 | — | — | 22,098 | — | 983,361 |
| Jeffrey Farrow | OPTION | 2025-03-05 | — | — | 30,628 | — | 895,011 |
| Bobak Azamian | OPTION | 2025-03-05 | — | — | 90,736 | — | 2,651,487 |
| Jeffrey Farrow | RSU | 2025-03-05 | — | — | 20,089 | — | 893,961 |
| Seshadri Neervannan | RSU | 2025-03-05 | — | — | 20,089 | — | 893,961 |
| Bryan Wahl | RSU | 2025-03-05 | — | — | 20,089 | — | 893,961 |
| Bryan Wahl | OPTION | 2025-03-05 | — | — | 30,628 | — | 895,011 |
| Aziz Mottiwala | OPTION | 2025-03-05 | — | — | 33,691 | — | 984,518 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Bobak Azamian | $2,648,284 | $0 | $2,651,487 | 0.0% |
| Seshadri Neervannan | 893,961 | 0 | 895,011 | 0.0% |
| Aziz Mottiwala | 983,361 | 0 | 984,518 | 0.0% |
| Jeffrey Farrow | 893,961 | 0 | 895,011 | 0.0% |
| Bryan Wahl | 893,961 | 0 | 895,011 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Aziz Mottiwala | Option | 4,082 | 19.59 | — |
| Seshadri Neervannan | Option | 4,345 | 19.59 | — |
| Seshadri Neervannan | RSU | 5,097 | — | 417,342 |
| Jeffrey Farrow | PSU | 7,508 | — | 614,755 |
| Seshadri Neervannan | PSU | 7,508 | — | 614,755 |
| Bobak Azamian | Option | 9,630 | 19.59 | — |
| Bobak Azamian | RSU | 11,300 | — | 925,244 |
| Seshadri Neervannan | Option | 15,037 | 15 | — |
| Aziz Mottiwala | Option | 15,037 | 15 | — |
| Seshadri Neervannan | RSU | 16,296 | — | 1,334,316 |
| Jeffrey Farrow | RSU | 20,089 | — | 1,644,887 |
| Seshadri Neervannan | RSU | 20,089 | — | 1,644,887 |
| Bobak Azamian | PSU | 22,318 | — | 1,827,398 |
| Jeffrey Farrow | RSU | 24,060 | — | 1,970,033 |
| Seshadri Neervannan | RSU | 24,060 | — | 1,970,033 |
| Jeffrey Farrow | Option | 26,719 | 35.5 | — |
| Seshadri Neervannan | Option | 26,719 | 35.5 | — |
| Aziz Mottiwala | Option | 26,719 | 35.5 | — |
| Jeffrey Farrow | Option | 30,628 | 44.54 | — |
| Seshadri Neervannan | Option | 30,628 | 44.54 | — |
| Bobak Azamian | Option | 31,327 | 15 | — |
| Aziz Mottiwala | Option | 33,691 | 44.54 | — |
| Bobak Azamian | RSU | 33,950 | — | 2,779,826 |
| Jeffrey Farrow | Option | 54,466 | 14.62 | — |
| Jeffrey Farrow | RSU | 55,763 | — | 4,565,874 |
| Bobak Azamian | RSU | 59,512 | — | 4,872,843 |
| Bobak Azamian | RSU | 69,364 | — | 5,679,524 |
| Bobak Azamian | Option | 77,034 | 35.5 | — |
| Bobak Azamian | Option | 90,736 | 44.54 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Wendy YarnoIndependent · Lead Independent Director · Compensation (Chair) · Commercial | $152,611 | $120,732 | $120,996 | $0 | $0 | $394,339 |
| Scott MorrisonIndependent · Audit (Chair) | 75,000 | 120,732 | 120,996 | 0 | 0 | 316,728 |
| Bhaskar ChaudhuriIndependent · Compensation · Science and Technology | 74,000 | 120,732 | 120,996 | 0 | 0 | 315,728 |
| William J. LinkIndependent · Compensation · Science and Technology | 71,500 | 120,732 | 120,996 | 0 | 0 | 313,228 |
| Andrew GoldbergIndependent · Audit · Nominating/Governance | 68,556 | 120,732 | 120,996 | 0 | 0 | 310,284 |
| Katherine GoodrichIndependent · Audit · Nominating/Governance | 65,000 | 120,732 | 120,996 | 0 | 0 | 306,728 |
| Rosemary CraneIndependent · Audit · Commercial · Departed during FY | 2,889 | — | — | 0 | 0 | 2,889 |
| Bobak AzamianEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| David E.I. PyottIndependent · Compensation · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $270,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $509,556 |
| Equity awards (grant-date value) | $724,392 |
| All other compensation | $0 |
| Total cost of the board | $1,233,948 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Tarsus Pharmaceuticals as a peer
Companies that benchmark against TARS
12 companies name TARS as a compensation peer
- Arcutis Biotherapeutics, Inc.ARQTFY2025
- ARDELYX, INC.ARDXFY2025
- ARS Pharmaceuticals, Inc.SPRYFY2025
- Aurinia Pharmaceuticals Inc.AUPHFY2025
- Evolus, Inc.EOLSFY2025
- HARROW, INC.HROWFY2025
- Humacyte, Inc.HUMAFY2025
- OCULAR THERAPEUTIX, INCOCULFY2025
- Phathom Pharmaceuticals, Inc.PHATFY2025
- Syndax Pharmaceuticals IncSNDXFY2025
- Verona Pharma plcVRNAFY2024
- Viridian Therapeutics, Inc.\DEVRDNFY2025
Each company listed discloses TARS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TARS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
KNSA Kiniksa Pharmaceuticals, Ltd.MNKD Mannkind Corp.CPRX Catalyst Pharmaceuticals, Inc.MIRM Mirum Pharmaceuticals, Inc.IRWD Ironwood Pharmaceuticals, Inc.RYTM Rhythm Pharmaceuticals, Inc.SWTX SpringWorks Therapeutics, Inc.HROW Harrow, Inc.ARQT Arcutis Biotherapeutics, Inc.ARDX Ardelyx, Inc.DAWN Day One Biopharmaceuticals, Inc.EOLS Evolus, Inc.OCUL Ocular Therapeutix, Inc.SUPN Supernus Pharmaceuticals. Inc.AUPH Aurinia Pharmaceuticals, Inc.
Peer reciprocity
The companies Tarsus Pharmaceuticals, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Harrow, Inc. (HROW)104Arcutis Biotherapeutics, Inc. (ARQT)105Ardelyx, Inc. (ARDX)106Evolus, Inc. (EOLS)107Ocular Therapeutix, Inc. (OCUL)108Aurinia Pharmaceuticals, Inc. (AUPH)109
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ocular Therapeutix, Inc. | 2025 | Pravin Dugel | $819,200 | $18,608,000 | $15,567,000 | $0 | $35,946,958 |
| 2 | Harrow, Inc. | 2025 | Mark Baum | 754,910 | 22,294,873 | 0 | 542,491 | 23,606,274 |
| 3 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 4 | SpringWorks Therapeutics, Inc. | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 5 | Supernus Pharmaceuticals. Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 6 | Kiniksa Pharmaceuticals, Ltd. | 2025 | Sanj Patel | 943,129 | 3,798,021 | 4,743,446 | 1,284,065 | 10,782,661 |
| 7 | Mirum Pharmaceuticals, Inc. | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 8 | Mannkind Corp. | 2025 | Michael Castagna | 789,436 | 7,689,480 | 0 | 675,757 | 9,300,485 |
| 9 | Ardelyx, Inc. | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 10 | Catalyst Pharmaceuticals, Inc. | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 11 | Arcutis Biotherapeutics, Inc. | 2025 | Todd Franklin Watanabe | 713,333 | 2,067,190 | 3,848,958 | 579,584 | 7,223,065 |
| 12 | Tarsus Pharmaceuticals, Inc. | 2025 | Bobak Azamian | 726,333 | 2,648,284 | 2,651,487 | 555,700 | 6,617,979 |
| 13 | Day One Biopharmaceuticals, Inc. | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 14 | Evolus, Inc. | 2025 | David Moatazedi | 775,000 | 3,886,569 | 1,296,697 | 429,000 | 6,412,214 |
| 15 | Aurinia Pharmaceuticals, Inc. | 2025 | Peter Greenleaf | 822,877 | 1,965,321 | 2,193,189 | 864,021 | 5,858,590 |
| 16 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 108% | Options 50 · RSU 50 | No | Pay Governance |
| Arcutis Biotherapeutics, Inc. | 125% | not disclosed | No | Pay Governance LLC |
| Ardelyx, Inc. | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Aurinia Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | WTW |
| Catalyst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Mercer LLC |
| Day One Biopharmaceuticals, Inc. | 123%% | Option 50 · RSU 50 | not disclosed | Compensia Inc. |
| Evolus, Inc. | 55% | not disclosed | No | Radford, an Aon Company |
| Harrow, Inc. | 100% | not disclosed | No | Mercer, Inc. |
| Ironwood Pharmaceuticals, Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Kiniksa Pharmaceuticals, Ltd. | not disclosed | Option 50 · RSU 25 · PSU 25 | not disclosed | Compensia, Inc. |
| Mannkind Corp. | 107% | PSU 55 · RSU 45 | Yes — Total Stockholder Return (TSR) relative to Russell 3000 Pharmaceutical & Biotechnology Index | Mercer LLC |
| Mirum Pharmaceuticals, Inc. | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| Ocular Therapeutix, Inc. | 145% | not disclosed | No | Aon |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| SpringWorks Therapeutics, Inc. | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Supernus Pharmaceuticals. Inc. | not disclosed | not disclosed | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-25 | 34,486,767 | 238,014 | 48,865 | 99.31% | Passed |
| 2025 | 2025-06-12 | 27,132,839 | 416,845 | 16,635 | 98.49% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-25 | 99.31%a |
| 2025 | 2025-06-12 | 98.49%b |
a. Approved under the standard stated in the filing — “Abstentions are not counted as a vote cast for or against the proposal and therefore have no effect on the outcome of the vote.”.
b. Approved under the standard stated in the filing — “Abstentions are not counted as a vote cast for or against the proposal and therefore have no effect on the outcome of the vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 26 : 1 |
|---|---|
| CEO total compensation | $6,617,979 |
| Median employee compensation | $251,525 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Scott Morrison | Director | 2026-06-12 | D | 2,954 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-15 | D | 1,928 | 63 | 121,348 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-15 | D | 10,572 | 62 | 655,147 | Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-15 | D | 2,954 | 62 | 183,384 | Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-15 | D | 27,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-15 | A | 27,881 | — | — | Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-16 | D | 14,396 | 61 | 877,436 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-06-17 | D | 4,582 | 61 | 280,602 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-06-17 | D | 5,418 | 62 | 334,887 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-25 | — | 2,821 | — | — | 3 insiders, 3 accrual rows | ||
| William J. Link | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-01 | D | 4,601 | 74 | 339,830 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-02 | D | 5,387 | 80 | 430,960 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-02 | D | 10,000 | 80 | 800,600 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-02 | D | 1,590 | 80 | 127,200 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 1,590 | 85 | 135,150 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 5,387 | 85 | 457,895 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 5,386 | 90 | 484,740 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 1,590 | 90 | 143,100 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-04 | D | 2,900 | 91 | 264,683 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-04 | D | 7,100 | 90 | 640,917 | Common | Form 4 ↗ |
| Seshadri Neervannan | Chief Operating Officer | 2026-09-04 | D | 4,564 | 85 | 387,940 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 759 | 79 | 59,961 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 11,675 | 78 | 914,503 | Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-09-15 | A | 201 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-15 | — | 704 | — | — | 3 insiders, 3 accrual rows | ||
| Wendy Yarno | Director | 2026-09-15 | A | 302 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 66 | 80 | 5,281 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | A | 201 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 57 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Scott Morrison | Director | 2026-06-12 | D | 2,954 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-15 | D | 1,928 | 63 | 121,348 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-15 | D | 10,572 | 62 | 655,147 | Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-15 | D | 2,954 | 62 | 183,384 | Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-15 | D | 27,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-15 | A | 27,881 | — | — | Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-16 | D | 14,396 | 61 | 877,436 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-06-17 | D | 4,582 | 61 | 280,602 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-06-17 | D | 5,418 | 62 | 334,887 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-25 | A | 806 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-06-25 | A | 806 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-25 | A | 1,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-01 | D | 4,601 | 74 | 339,830 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-02 | D | 5,387 | 80 | 430,960 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-02 | D | 10,000 | 80 | 800,600 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-02 | D | 1,590 | 80 | 127,200 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 1,590 | 85 | 135,150 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 5,387 | 85 | 457,895 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 5,386 | 90 | 484,740 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 1,590 | 90 | 143,100 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-04 | D | 2,900 | 91 | 264,683 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-04 | D | 7,100 | 90 | 640,917 | Common | Form 4 ↗ |
| Seshadri Neervannan | Chief Operating Officer | 2026-09-04 | D | 4,564 | 85 | 387,940 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 759 | 79 | 59,961 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 11,675 | 78 | 914,503 | Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-09-15 | A | 201 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 201 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-09-15 | D | 302 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-09-15 | A | 302 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 66 | 80 | 5,281 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | A | 201 | — | — | Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-09-15 | D | 201 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Sources (109 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Bobak Azamian. DEF 14A, filed 2026-04-28. Section “2025 SUMMARY COMPENSATION TABLE” · page 25. As printed: 6,617,979. View filing ↗
- Section 01, Aziz Mottiwala. DEF 14A, filed 2026-04-28. Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 2,789,529. View filing ↗
- Section 01, Jeffrey Farrow. DEF 14A, filed 2026-04-28. Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 2,677,617. View filing ↗
- Section 01, Seshadri Neervannan. DEF 14A, filed 2026-04-28. Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 2,628,172. View filing ↗
- Section 01, Bryan Wahl. DEF 14A, filed 2026-04-28. Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 2,560,205. View filing ↗
- Section 03, Bobak Azamian RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Seshadri Neervannan OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Aziz Mottiwala RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jeffrey Farrow OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Bobak Azamian OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jeffrey Farrow RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Seshadri Neervannan RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Bryan Wahl RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Bryan Wahl OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Aziz Mottiwala OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 26 : 1. View filing ↗
- Section 08, Wendy Yarno. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 394,339. View filing ↗
- Section 08, Scott Morrison. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 316,728. View filing ↗
- Section 08, Bhaskar Chaudhuri. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 315,728. View filing ↗
- Section 08, William J. Link. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 313,228. View filing ↗
- Section 08, Andrew Goldberg. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 310,284. View filing ↗
- Section 08, Katherine Goodrich. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 306,728. View filing ↗
- Section 08, Rosemary Crane. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 2,889. View filing ↗
- Section 08, Bobak Azamian. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, David E.I. Pyott. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Scott Morrison 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Goldberg 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Goldberg 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wendy Yarno 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wendy Yarno 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Goodrich 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Goodrich 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bhaskar Chaudhuri 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bhaskar Chaudhuri 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Morrison 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Goodrich 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Farrow 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Farrow 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Farrow 2026-06-16. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bobak Azamian 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bobak Azamian 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E.I. Pyott 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E.I. Pyott 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E.I. Pyott 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wendy Yarno 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wendy Yarno 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bhaskar Chaudhuri 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bhaskar Chaudhuri 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Morrison 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Morrison 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Goldberg 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Goldberg 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Goodrich 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Goodrich 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wendy Yarno 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Yeu Lin 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Yeu Lin 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bobak Azamian 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Yeu Lin 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Yeu Lin 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Yeu Lin 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Yeu Lin 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Yeu Lin 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bobak Azamian 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bobak Azamian 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seshadri Neervannan 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E.I. Pyott 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wendy Yarno 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wendy Yarno 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Link 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E.I. Pyott 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-29. Item 5.07 · say-on-pay result. As reported: 99.31% (votes for as printed: 34,486,767). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-18. Item 5.07 · say-on-pay result. As reported: 98.49% (votes for as printed: 27,132,839). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 509,556 + equity 724,392 + all other 0 = 1,233,948, summed across the director compensation table rows.
- Ocular Therapeutix, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Ocular Therapeutix, Inc.'s own proxy. As printed: 35,946,958. View filing ↗
- Harrow, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Harrow, Inc.'s own proxy. As printed: 23,606,274. View filing ↗
- Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
- SpringWorks Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. View filing ↗
- Supernus Pharmaceuticals. Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals. Inc.'s own proxy. As printed: 15,501,557. View filing ↗
- Kiniksa Pharmaceuticals, Ltd., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Kiniksa Pharmaceuticals, Ltd.'s own proxy. As printed: 10,782,661. View filing ↗
- Mirum Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Mirum Pharmaceuticals, Inc.'s own proxy. As printed: 10,441,224. View filing ↗
- Mannkind Corp., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Mannkind Corp.'s own proxy. As printed: 9,300,485. View filing ↗
- Ardelyx, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ardelyx, Inc.'s own proxy. As printed: 7,796,171. View filing ↗
- Catalyst Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. View filing ↗
- Arcutis Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcutis Biotherapeutics, Inc.'s own proxy. As printed: 7,223,065. View filing ↗
- Tarsus Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Tarsus Pharmaceuticals, Inc.'s own proxy. As printed: 6,617,979. View filing ↗
- Day One Biopharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Day One Biopharmaceuticals, Inc.'s own proxy. As printed: 6,560,577. View filing ↗
- Evolus, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Evolus, Inc.'s own proxy. As printed: 6,412,214. View filing ↗
- Aurinia Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Aurinia Pharmaceuticals, Inc.'s own proxy. As printed: 5,858,590. View filing ↗
- Ironwood Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. View filing ↗
- Section 10a, Harrow, Inc. reciprocity. DEF 14A. Harrow, Inc. names Tarsus Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Arcutis Biotherapeutics, Inc. reciprocity. DEF 14A. Arcutis Biotherapeutics, Inc. names Tarsus Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Ardelyx, Inc. reciprocity. DEF 14A. Ardelyx, Inc. names Tarsus Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Evolus, Inc. reciprocity. DEF 14A. Evolus, Inc. names Tarsus Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Ocular Therapeutix, Inc. reciprocity. DEF 14A. Ocular Therapeutix, Inc. names Tarsus Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Aurinia Pharmaceuticals, Inc. reciprocity. DEF 14A. Aurinia Pharmaceuticals, Inc. names Tarsus Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗